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Challenges to Estimating Norovirus Disease Burden
Catherine Yen and Aron J. Hall
Centers for Disease Control and Prevention, Atlanta, Georgia
In the United States, acute gastroenteritis (AGE) is a significant cause of morbidity, 
accounting for approximately 179 million illnesses annually [1]. Noroviruses are recognized 
as the leading cause of AGE across all ages and are responsible for approximately 21 million 
annual illnesses. However, before 2006, rotaviruses accounted for the majority of severe 
AGE cases among children under 5 years of age [2]. The introduction of rotavirus vaccines 
into the recommended infant immunization schedule in 2006 has resulted in a substantial 
overall decline in pediatric rotavirus disease (and thus AGE) in the United States, with 
evidence of indirect benefits among some older age groups [3, 4]. Given these declines in 
the post-rotavirus vaccine era, it is thought that noroviruses are now likely the leading cause 
of AGE among children, although substantiating this assumption with robust data on the 
burden of norovirus disease is not a straightforward endeavor.
There are several challenges to estimating norovirus disease burden, many of which relate to 
the lack of a rapid and sensitive clinical assay for diagnosis of norovirus infections. Because 
norovirus disease is a relatively nonspecific syndrome that can manifest similar symptoms as 
other agents of AGE, laboratory confirmation is necessary to identify sporadic cases. 
However, current diagnostics rely on molecular methods that are largely restricted to public 
health and research laboratories, and no commercial assay has been approved for use in the 
United States to diagnose individual norovirus cases. As a result, there is no case or clinical 
laboratory-based reporting system for sporadic norovirus disease. Likewise, norovirus-
specific codes in administrative data, such as insurance claims, are typically used only when 
there is laboratory confirmation and thus are highly insensitive. Moreover, only 
approximately 15% of patients with AGE in the community seek medical attention, and of 
those who seek medical attention, diagnostic testing is requested from only 13% [5]. These 
healthcare use indicators can vary significantly based on patient factors (eg, age, 
socioeconomic status, insurance coverage) and healthcare provider practices, which further 
complicate attempts to extrapolate findings from inpatients and outpatients to the 
community. Given these challenges, national surveillance for norovirus disease in the United 
States is limited to outbreaks, which are reported passively and therefore are subject to 
tremendous variability, and vastly underestimate the overall burden of disease.
In this month's edition of the Journal of the Pediatric Infectious Diseases, Koo et al present 
an impressive longitudinal epidemiologic study to assess trends in viral etiologies of AGE at 
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a large pediatric hospital [6]. The authors tested over 3000 stool specimens for enteric 
viruses over an 8.5-year period, during which time they report significant reduction in 
rotavirus prevalence after introduction of rotavirus vaccine and subsequent emergence of 
norovirus as the leading viral enteropathogen. Although there likely was a real shift in the 
etiologic distribution of pediatric AGE over the study period, interpretation of the reported 
disease trends is complicated by the surveillance limitations mentioned above. For example, 
the authors tested stool specimens that were submitted for viral testing, presumably for 
rotavirus antigen detection primarily. This selection and screening process may have yielded 
a biased sample of all patients with AGE (eg, inclusion criterion of physician request may 
result in overrepresentation of the pathogen being ordered for testing and thereby 
underrepresent other etiologies), thus making it more difficult to generalize the study 
findings. In addition, the absence of an approved commercial diagnostic assay for norovirus 
necessitated reliance on nonstandard diagnostic techniques, which changed over the course 
of the study from conventional reverse transcription-polymerase chain reaction (RT-PCR) to 
a more sensitive real-time RT-PCR assay. This change in testing practices makes it more 
difficult to determine whether the described trends are a true reflection of changes in 
norovirus disease burden, although the authors reassuringly note high concordance between 
the 2 assays in a subset of specimens tested by both methods. Finally, the use of laboratory 
testing data without a well-defined catchment population did not allow for the calculation of 
disease incidence rates, which provide a more comprehensive estimation of disease burden 
than simply etiologic prevalence. Nonetheless, the study by Koo et al demonstrates an 
important change in the leading causes of severe pediatric AGE, which may reflect a similar 
pattern in the overall disease burden [6].
Until simple, sensitive, and rapid testing methods for norovirus are widely available in 
clinical settings, there are a few methodologic approaches that can be taken to improve our 
understanding of norovirus disease burden and, in turn, better guide diarrheal disease 
prevention efforts and clinical management practices. The ideal strategy is active population-
based surveillance, which involves systematic sampling of all AGE cases within a known 
catchment area and allows for the calculation of incidence rates of disease. Examples of this 
approach include the Sensor Study, conducted in the Netherlands, and the studies of 
Infectious Intestinal Disease, conducted in the United Kingdom [7, 8]. Because this 
approach is expensive and labor-intensive, less costly approaches can be taken that overcome 
at least some of the challenges noted above. Passive testing of specimens submitted for 
routine clinical purposes, as exemplified by Koo et al, can be a viable approach if sample 
selection and diagnostics are performed consistently and if the catchment population can be 
defined. This approach has been used previously to estimate outpatient norovirus incidence 
among members of a health maintenance organization in Georgia [7]. Alternatively, indirect 
modeling methods can be used to estimate the fraction of unspecified AGE that are likely 
due to norovirus, using population-based administrative data on healthcare encounters or 
mortality [9, 10]. Consistent use of these surveillance platforms and analytical strategies 
over time can help elucidate trends in norovirus disease burden, which appear to be quite 
dynamic given the rapid evolution and frequent emergence of new strains.
Although it is challenging to obtain precise estimates, noroviruses clearly cause a substantial 
disease burden, and their relative importance is increasing due to declines in rotavirus 
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disease. As norovirus vaccine development continues to progress [11], it is crucial that 
accurate, long-term disease norovirus burden estimates be developed in a variety of settings 
to help establish a baseline of the global burden and to identify priority target populations. 
This in turn will allow for accurate measurement of the impact of interventions, such as 
vaccines, and will help guide future policy decisions regarding the prevention and control of 
AGE.
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